ScPharmaceuticals Sees US Application Submission For Furoscix In Q3

By Vandana Singh8 days ago

  • ScPharmaceuticals Inc (NASDAQ: SCPH) announced that after the Type A meeting with the FDA, the agency does not require any modifications to the device, nor it asked the company to conduct additional clinical studies to demonstrate the safety and efficacy of Furoscix.
  • In December last year, the company received a Complete Response Letter due ...

Full story available on Benzinga.com

Continue read on benzinga.com